Month: September 2021

Energy Fuels Establishes the San Juan County Clean Energy Foundation with Potential to Contribute Millions to Local Communities

Posted on by Admin

 

 


Energy Fuels Establishes the San Juan County Clean Energy Foundation with Potential to Contribute Millions to Local Communities

 

BLANDING, Utah, Sept. 16, 2021 /CNW/ – At its recent open house showcasing its uranium and rare earth businesses for local and national dignitaries and industry leaders, Energy Fuels Inc. (“Energy Fuels” or the “Company”) announced the establishment of the San Juan County Clean Energy Foundation, a fund specifically designed to contribute to the communities surrounding Energy Fuels’ White Mesa Mill in Southeastern, Utah. 

          This week, Energy Fuels deposited $1 million into the Foundation and anticipates providing ongoing annual funding equal to 1% of the Mill’s future revenues, providing funding to support the local economy and local priorities. The Foundation will focus on supporting education, the environment, health/wellness, and economic advancement in the City of Blanding, San Juan County, the White Mesa Ute Community, the Navajo Nation and other area communities. 

          “The communities that surround our facility deserve to share in the benefits of the Mill’s clean energy future,” said Mark Chalmers, CEO of Energy Fuels. “Uranium, which is the fuel for carbon-free, emission-free baseload nuclear power, is one of the cleanest forms of energy in the world. The rare earth’s we are now producing are used for the manufacture of permanent magnets for electric vehicles, wind turbines and other clean energy and modern technologies, and the thorium and other radioisotopes we are evaluating for recovery from our rare earth and uranium processing streams have the potential to provide the isotopes needed for emerging targeted alpha therapy cancer-fighting therapeutics. The very heart of our business – uranium and rare-earth production and recycling – helps us play a big part in addressing global climate change, reducing air pollution, and making the world a cleaner and healthier place. We see San Juan County as becoming a critical minerals hub for the U.S., and we believe the Foundation is truly the best way to make an impact and difference in the lives of those who work alongside us as we pursue these goals.”

          Company executives met with local community members to better understand and identify how the Foundation will strategically support the local communities and how to best structure the Foundation. 

          “Energy Fuels has long been a major contributor to not only the employment base of the community but also for the well-being and prosperity of this region,” said Blanding’s Mayor Joe B. Lyman. “Over the last year, the Company has met with local community members to understand and identify needs in the area. The formation of the Foundation is a culmination of these efforts and the beginning of a long-term commitment to improve the quality of life for everyone in the San Juan County area to help us reach our full potential.” To ensure that the Foundation’s contributions are well-planned and correspond to the specific needs and aspirations of the communities, the Foundation will have a community-based Advisory Board to help it determine the best allocation for the funds.  

          “The processing of rare earths at the White Mesa Mill, in addition to processing and recycling uranium, is one of the best opportunities I have seen in my entire 40+ year career, as electric vehicles, renewable energy systems, and other clean energy and advanced technologies drive demand,” continued Mr. Chalmers. “And, the potential to also extract isotopes that can be used to fight cancer is a very important added opportunity. Investing back into the San Juan County community will give us the opportunity to help support and catalyze sustainable economic and community development, beyond good jobs and more tax revenues.” 

          With a population of a little more than 3,000 people, Blanding is the most populous city in San Juan County. Economic contributors include mineral processing, mining, agriculture, local commerce, tourism, and transportation. The community is also a gateway to nearby natural, cultural and archaeological resources. Energy Fuels’ rare earth initiative will only involve mineral processing, and it is not expected to involve any new mining in the region. 

          Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8?to major nuclear utilities. Energy Fuels also produces vanadium from certain projects, as market conditions warrant, as well as rare earth carbonate. With corporate offices in?Lakewood, Colorado, near?Denver, and all of its assets and employees in?the United States, Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in?Utah, the Nichols Ranch in-situ recovery (ISR) Project in?Wyoming, and the Alta Mesa ISR Project in?Texas. Energy Fuels is a publicly traded company on the NYSE under the trading symbol “UUUU,” and its common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’ website is?www.energyfuels.com  

CAUTIONARY STATEMENTS REGARDING FORWARD LOOKING STATEMENTS

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information may relate to future events or future performance of Energy Fuels. All statements in this release, other than statements of historical facts, with respect to Energy Fuels’ objectives and goals, as well as statements with respect to its beliefs, plans, objectives, expectations, anticipations, estimates, and intentions, are forward-looking information. Specific forward-looking statements in this discussion include, but are not limited to, the following: any expectation as to future production of uranium at the Mill; any expectation as to future production of rare earth products at the Mill; any expectation as to future production of thorium and other radioisotopes for use in emerging targeted alpha therapies; any expectation as to future revenues at the Mill; any expectation that San Juan County will become a critical minerals hub for the U.S.; any expectation as to any ongoing annual funding for the Foundation or the longevity of the Foundation; any expectation that the Foundation will provide the potential to contribute millions to local communities; any expectation as to the manner in which the Foundation will distribute or invest its funds; and any expectation that the Foundation’s money will help support and catalyze sustainable economic and community development, beyond good jobs and more tax revenues. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates” or “believes”, or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: commodity prices; processing difficulties and upsets; available supplies of monazite sands; the capital and operating costs associated with the recovery of uranium, rare earth products, thorium and other radioisotopes at the Mill; licensing, permitting and regulatory delays; litigation risks; competition from others; market factors, including future demand for and prices realized from the sale of uranium, rare earth products, and thorium or other radioisotopes produced at the Mill; and any changes that may be made to the structure, funding or term of the Foundation if the Company determines at any time that the Foundation is not achieving its objectives or to better meet its objectives. Forward-looking statements contained herein are made as of the date of this news release, and Energy Fuels disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. Energy Fuels assumes no obligation to update the information in this communication, except as otherwise required by law.

SOURCE Energy Fuels Inc.

Helius Medical Technologies (HSDT)(HSM:CA) – CMS to Scrap MCIT? Implications for Helius

Posted on by Admin

Thursday, September 16, 2021

Helius Medical Technologies (HSDT)(HSM:CA)
CMS to Scrap MCIT? Implications for Helius

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Gregory Aurand, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    MCIT Concerns. The Centers for Medicare and Medicaid Services (CMS) has announced it is planning to scrap the proposed Medicare Coverage of Innovative Technology (MCIT) payment rule that would have allowed four years of Medicare coverage for breakthrough device designated technologies. While an unfortunate setback, we do not believe the potential loss of MCIT to be material to the Helius story.

    Not Quite Dead Yet.  While CMS may be looking to scrap MCIT following a 30 day comment period, the proposal was recently included in a discussion draft for the 21st Century Cures Act which is expected to come up in next year’s legislative calendar. So a form of MCIT may be revised shortly in any case …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Indonesia Energy Corp (INDO) – Results for 2nd well surpass expectations

Posted on by Admin

Thursday, September 16, 2021

Indonesia Energy Corp (INDO)
Results for 2nd well surpass expectations

Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. It holds two oil and gas assets through its subsidiaries in Indonesia: one producing block (the Kruh Block) and one exploration block (the Citarum Block). The Kruh Block is located to the northwest of Pendopo, Pali, South Sumatra. The Citarum Block is located to the south of Jakarta.

Michael Heim, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Indo announced that it has discovered oil in its Kruh 26 well. The discovery follows similar success at the initial Kruh 25 well and was largely expected. Drilling was done in only 18 days at a cost below initial expectations of $1.5 million. Drilling encountered a larger-than-expected pay zone implying that reserves may be higher than expected. Production for the first two wells is expected in the fourth quarter, in line with expectations.

    Drilling continues albeit with fewer wells to be drilled in 2021.  The company still plans to drill 18 wells in 2021-23 but will only do three in 2021 instead of five. The company has faced several drilling delays since it started its drilling program, mostly due to COVID issues. The most recent delay does not change our overall profile of valuation for the company, but we will be watching future …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Energy Fuels Hosts Mining, Environmental and Political Heavyweights to Showcase Uranium Activities and Introduce Production of Rare Earths at its Blanding, Utah Facility

Posted on by Admin

 

 


Energy Fuels Hosts Mining, Environmental and Political Heavyweights to Showcase Uranium Activities and Introduce Production of Rare Earths at its Blanding, Utah Facility

 

Shipments of commercial quantities of rare earths from Energy Fuels’ White Mesa Mill in Blanding represent a milestone in the creation of a new supply chain reducing dependence on foreign suppliers, while boosting significant economic potential to the area

BLANDING, Utah, Sept. 16, 2021 /CNW/ – Energy Fuels’ President and CEO, Mark Chalmers is hosting business, community and industry heavyweights in Blanding, Utah to introduce the commencement of production and shipments of an intermediate rare earth element (“REE”) product, called mixed rare earth carbonate (“RE Carbonate”), at its Utah-based White Mesa Mill (the “Mill”). Approximately 15 containers of RE Carbonate (300 tonnes of product) produced at the Mill is being shipped to Europe where it will be processed into separated rare earth oxides and other value-added RE compounds, thereby creating a new U.S. to Europe RE supply chain along with new opportunities and financial benefits for the surrounding communities. The Mill will be producing rare earths as a complement to its established uranium production business.

The Company will also showcase its U.S. industry-leading uranium production capabilities. Energy Fuels has been the largest producer of uranium in the U.S. for the past several years, boasting more uranium production facilities, mines and capacity than any other U.S. company. The White Mesa Mill is the largest uranium production facility in the US and America’s only operating uranium mill. Uranium is seeing increased interest recently, as it is the fuel for nuclear energy, which is the largest source of clean, carbon free energy in the U.S.

REEs are necessary in the production of hundreds of everyday and specialty items with a wide range of consumer applications, including cell phones, computer hard drives, electric and hybrid vehicles, and flat screen monitors and televisions. They also have significant national defense uses including electronic displays, guidance systems, lasers, and radar and sonar systems. Furthermore, with the global push to reduce greenhouse gas emissions, the expansion of green technologies such as solar and wind will continue to play a critical role, and REEs are a fundamental raw material used in the manufacturing of these clean energy sources. There are currently no U.S. companies producing separated REE oxides or any other advanced or value-added REE compounds, thereby making the US 100% dependent on the importation of these critical materials. Energy Fuels is determined to reverse that reliance and lessen the risk of disruption to the clean energy economy and our national defense. 

“This is an exciting time for all of us at Energy Fuels in both the uranium and rare earth sectors,” said Chalmers. “We believe the San Juan County community will benefit greatly from this rare earth initiative, as it will offer not only a safe, environmentally sensible, and domestically-generated product, but it will also stimulate local employment and be an economic boost to the area.” The White Mesa Mill is currently one of the largest private employers in the county, and it is estimated that this new rare earth effort could result in an investment of hundreds of millions of dollars into the facility, which could translate into 100+ jobs in the region—one of the largest reinvestments this region has seen in decades. “In addition to the economic benefits to Utah, restoring rare earth production to the United States will greatly benefit the entire U.S. economy and manufacturing sector by providing a domestic source of clean energy materials produced to the highest global standards for environmental protection, sustainability and human rights, while also allowing for source validation and tracking from mining through final end-use applications,” added Chalmers. “With the increased demand for rare earths—up to a fivefold demand increase over the next 10 years—we will need all hands-on deck. Combined with the current resurgence in uranium, rare earths represent a truly an immense opportunity for San Juan County, the State of Utah, and the United States as a whole.”

This move by Energy Fuels comes at a time when the Biden administration has made it a priority to reestablish the rare earths industry in the US. Currently, China dominates every aspect of the REE industry from mining to the manufacturing of REE magnets. In the early 1990’s, China produced 38% of world’s REEs, the US produced 33%, Australia produced 12%, and Malaysia and India produced a combined five percent with several smaller countries making up the rest (Source: What are rare earth elements, and why are they important? | American Geosciences Institute). However, a significant shift in those percentages occurred, and by 2011 97% of the world’s REEs were produced in China. While China is expected to continue as the dominant player in the global REE industry, Energy Fuels believes it can create a low-cost, secure domestic alternative for end-users seeking diversity of supply and competition.

Headquartered in Lakewood, Colorado, Energy Fuels currently plans to ramp up to process up to at least 15,000 tons of monazite per year at its White Mesa Mill. This amount of monazite contains roughly 50% of current U.S. rare earth demand, along with significant quantities of uranium, which will be recovered for use in domestic nuclear energy production.  “Energy Fuels and our partner, Neo Performance Materials, have made significant steps toward restoring critical U.S. and European rare earth supply chains,” added Chalmers. “We are strategically seeking to increase our rare earth carbonate production in the coming years, since we first started acquiring monazite ore produced in the State of Georgia earlier this year.”

Successfully producing REEs, and physically delivering the first containers of RE Carbonate to Neo for separation, is an important achievement, not only for Energy Fuels, but also for the U.S. government and its efforts to restore critical rare earth supply chains. This is also good news for end-users of rare earth products in the U.S., Europe, Japan and elsewhere who seek alternative sources of rare earths produced in the U.S. and Europe that adhere to the highest global regulations and standards of environmental protection and sustainability as well as keeping a close eye on human rights.

Because monazite contains naturally occurring radioactive elements, including uranium, the White Mesa Mill is the ideal location to process this valuable material. The Mill will recover the uranium from the monazite, which will be used for the generation of clean nuclear energy. The Mill is also evaluating the recovery of thorium which has potential uses in advanced nuclear technologies along with medical isotopes needed for emerging targeted alpha cancer therapies. In addition, the monazite that is received from Georgia contains over 50% REEs, which means Energy Fuels can recover large quantities of REEs while generating relatively tiny amounts of waste. “We have an exceptional track record of environmental protection and regulatory compliance at the Mill. We also have a lot of experience in safely handling and working responsibly with low-level, natural radioactive elements contained in a variety of uranium ores and recycled alternate feed materials,” stated Curtis Moore, Energy Fuels’ VP of Marketing and Corporate Development. “Monazite sand contains roughly the same percentage of uranium as the ore found in mines in the Four Corners’ region. So, we know we will responsibly process it for the recovery of the raw materials needed for various clean energy and advanced technologies. The safety of our community and our employees is and will always remain paramount. We also are evaluating how we can do more for our local communities, particularly local Navajo, Ute, and other Native American communities.”

“Energy Fuels recognizes the lingering distrust in communities that witnessed and experienced the health and environmental impacts from historic Cold War uranium mining operations, which continue to impact perceptions. We are deeply committed to addressing the world’s most pressing environmental issues, while advancing toward the electrification of the world economy. We believe that unlocking the value of domestically produced monazite and the domestic production of rare earths, combined with our existing uranium business, is a significantly positive step.” Energy Fuels has and continues to be profoundly committed to responsible and modern mining and production, and all U.S. uranium and REE production is done to the highest global standards for environmental protection and human rights.

About Energy Fuels: Energy Fuels is a leading US-based uranium mining company, supplying U3O8 to major nuclear utilities. Energy Fuels also produces vanadium for certain projects, as market conditions warrant, as well as rare earth carbonate. With corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees in the United States, Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch ISR Project in Wyoming, and the Alta Mesa ISR Project in Texas. Energy Fuels’ website is www.energyfuels.com.

CAUTIONARY STATEMENTS REGARDING FORWARD LOOKING STATEMENTS

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information may relate to future events or future performance of Energy Fuels. All statements in this release, other than statements of historical facts, with respect to Energy Fuels’ objectives and goals, as well as statements with respect to its beliefs, plans, objectives, expectations, anticipations, estimates, and intentions, are forward-looking information. Specific forward-looking statements in this discussion include, but are not limited to, the following: any expectation as to future production of uranium at the Mill; any expectation as to future production of rare earth products at the Mill or creation of a new U.S. to Europe supply chain; any expectation as to the Company’s ability to increase rare earth carbonate production; any expectations as to increased demand for rare earths; any expectation as to future production of thorium and other radioisotopes for use in emerging targeted alpha therapies; any expectation as to future revenues at the Mill; any expectation that San Juan County or Utah will realize significant economic benefits or that the Company’s rare earth initiative will create 100+ jobs; any expectation that Energy Fuels will reverse America’s reliance on imports or lessen the risk of disruption for critical minerals; any expectation that Energy Fuels will create a low-cost, secure domestic alternative for end-users seeking diversity of supply and competition. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates” or “believes”, or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: commodity prices; processing difficulties and upsets; available supplies of monazite sands; the capital and operating costs associated with the recovery of uranium, rare earth products, thorium and other radioisotopes at the Mill; licensing, permitting and regulatory delays; litigation risks; competition from others; market factors, including future demand for and prices realized from the sale of uranium, rare earth products, and thorium or other radioisotopes produced at the Mill. Forward-looking statements contained herein are made as of the date of this news release, and Energy Fuels disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. Energy Fuels assumes no obligation to update the information in this communication, except as otherwise required by law.

SOURCE Energy Fuels Inc.

QuickChek – September 16, 2021

Posted on by Admin



Neovasc Announces FDA Approval of COSIRA-II Clinical Trial

Neovasc announced that it has received FDA approval for the Investigational Device Exemption (“IDE”) regarding the COSIRA-II IDE Clinical Trial

Research, News & Market Data on Neovasc



Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial

Ayala Pharmaceuticals announced new preliminary clinical data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial

Research, News & Market Data on Ayala Pharmaceuticals

Watch recent presentation from Ayala Pharmaceuticals



Pro Football Retired Players Association Announces Partnership with Esports Entertainment Group for Its Gridiron Gaming Initiative

Esports Entertainment Group announced it has signed a partnership agreement with the Pro Football Retired Players Association

Research, News & Market Data on EEG

Watch recent presentation from EEG



Energy Fuels Establishes the San Juan County Clean Energy Foundation with Potential to Contribute Millions to Local Communities

Energy Fuels announced the establishment of the San Juan County Clean Energy Foundation, a fund specifically designed to contribute to the communities surrounding Energy Fuels’ White Mesa Mill in Southeastern, Utah

Energy Fuels Hosts Mining, Environmental and Political Heavyweights to Showcase Uranium Activities and Introduce Production of Rare Earths at its Blanding, Utah Facility

Energy Fuels announced the commencement of production and shipments of an intermediate rare earth element product, called mixed rare earth carbonate, at its Utah-based White Mesa Mill

Research, News & Market Data on Energy Fuels

Watch recent presentation from Energy Fuels

 

Stay up to date. Follow us:

 

Pro Football Retired Players Association Announces Partnership with Esports Entertainment Group for Its Gridiron Gaming Initiative

Posted on by Admin

 


Pro Football Retired Players Association Announces Partnership with Esports Entertainment Group for Its Gridiron Gaming Initiative

 

Newark, New Jersey and Arlington, Virginia–(Newsfile Corp. – September 16, 2021) – Esports Entertainment Group, Inc. (NASDAQ: GMBL) (NASDAQ: GMBLW) (or the “Company”) has signed a partnership agreement with the Pro Football Retired Players Association (PFRPA), a national membership organization that develops benefits and programs for retired NFL players, to be its official esports partner and tournament platform provider. The partnership will broaden the reach of PFRPA’s Gridiron Gaming initiative through a multi-tiered program, focused on expanding retired NFL players’ presence in esports, while producing unique fan engagement experiences. The comprehensive program will include learning opportunities, live-streamed content and virtual and in-person tournaments.

“Esports Entertainment Group brings a wealth of knowledge, innovation and expertise, all important factors in our decision to develop this strategic partnership for Gridiron Gaming,” said PFRPA Senior Director Joe Agbasi. “When we started this esports program, we set out to create engaging tournaments for our retired NFL players, esports athletes, gaming enthusiasts and fans. By teaming up with EEG, we can follow through on those aspirations while developing fun, exciting content. We’re proud to partner to offer interactive, family-friendly experiences for patrons interested in gaming and esports.”

Virtual tournaments will be operated through the Company’s Esports Gaming League platform, and in-person events will be held at Helix eSports facilities.

“We’re really excited to come together with the PFRPA and help bring a truly unique experience to their community,” said Magnus Leppäniemi, President of Esports at Esports Entertainment Group. “The partnership includes a great opportunity for players to engage their fan base through a variety of esports activities including in person events and streaming.”

The Company’s esports tournament platform enables live and online events and tournaments where gamers can compete and enjoy a wide range of content relating to esports and video games on a proprietary technology platform. Services include full turnkey esports events, live broadcast production, game launches and online branded tournaments.

“Esports has grown and keeps growing in popularity over the years, so I’m so glad we’re in the game,” said Jack Youngblood, NFL Hall of Famer and PFRPA Board Member. “To have the opportunity to team up with a premier partner that understands how to bring together different generations, while having fans of new and traditional sports meet in the same arena, is something special.”

Gridiron Gaming is PFRPA’s esports initiative that provides retired players an opportunity to compete again, while offering fans a chance to engage with their NFL heroes. Gridiron Gaming launched in 2019 and has since produced several esports tournaments.

About Pro Football Retired Players Association (PFRPA)

PFRPA is a champion for retired NFL players, dedicated to bettering the lives of those who contributed to the game. PFRPA, the first court-established retired NFL player organization, through its leadership and dedication, has been on a mission to solidify and preserve the legacy of retired NFL players. Through the Greater Good Fund, PFRPA’s 501(c)(3) charitable foundation, PFRPA develops various health and welfare programs, designed exclusively for retired NFL players. The Football Greats Alliance, PFRPA’s licensing agency, develops partnerships to drive meaningful revenue for retired NFL players and provide revenue for the Greater Good Fund to support all retired players. To date, more than 10,000 retired players and more than 2,500 players’ spouses have enrolled in PFRPA insurance benefits. For more information about PFRPA, visit www.pfrpa.com.

About Esports Entertainment Group

Esports Entertainment Group is a full stack esports and online gambling company fueled by the growth of video-gaming and the ascendance of esports with new generations. Our mission is to help connect the world at large with the future of sports entertainment in unique and enriching ways that bring fans and gamers together. Esports Entertainment Group and its affiliates are well-poised to help fans and players to stay connected and involved with their favorite esports. From traditional sports partnerships with professional NFL/NHL/NBA/FIFA teams, community-focused tournaments in a wide range of esports, and boots-on-the-ground LAN cafes, EEG has influence over the full-spectrum of esports and gaming at all levels. The Company maintains offices in New Jersey, the UK and Malta. For more information visit www.esportsentertainmentgroup.com.

Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact:
U.S. Investor Relations
RedChip Companies, Inc.
Dave Gentry
407-491-4498

dave@redchip.com

Media Inquiries
brandon.apter@esportsentertainmentgroup.com

Investor Relations Inquiries
Jeff@esportsentertainmentgroup.com

Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC

Posted on by Admin


Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC

 

– Posters presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021

– Preliminary data showed meaningful clinical activity of AL101 6mg monotherapy with 70% disease control rate

– AL101 was well tolerated with manageable side effects

REHOVOT, Israel and WILMINGTON, Del., Sept. 16, 2021 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced new preliminary clinical data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch-activating mutations. The data is being presented at the 2021 ESMO Virtual Congress as an ePoster. In a separate ePoster presentation, Ayala presented new preclinical results evaluating the potential of AL101 in combination with approved cancer therapies for dual targeting of ACC tumours.

“ACC is an orphan disease with no approved therapies and patients with Notch mutations have a more aggressive disease course and poorer survival outcomes as compared to patients with Notch wild-type. R/M ACC remains a significant area of unmet need, and I am encouraged by the preliminary results that AL101 monotherapy has demonstrated to-date. Coupled with new preclinical data showing that AL101 in combination with approved targeted therapies could potentially treat a greater proportion of ACC tumors, regardless of Notch mutations, it will be exciting to see how AL101 may be developed as a viable treatment option for R/M ACC patients,” said Alan L. Ho, M.D., Ph.D., Medical Oncology, Memorial Sloan Kettering Cancer Center and Lead Investigator in The ACCURACY Trial. “While these results are still preliminary, the safety profile of AL101 and the disease control rate of 70% are promising indicators in this incredibly difficult to treat patient population.”  

“The preliminary safety and efficacy data from the 6mg cohort of our ongoing ACCURACY trial of AL101 highlights a favourable profile. We are pleased to see that AL101’s safety profile continues to be tolerable and manageable, providing us with potential dosing flexibility as we continue to advance our development plans,” said Gary Gordon, M.D., Ph.D., Chief Medical Officer of Ayala. “We continue to see strong potential for AL101 to transform the treatment landscape for R/M ACC patients with Notch mutations and we look forward to reporting additional clinical data in 2022.”

Preliminary Safety and Efficacy Data from 6mg Cohort of ACCURACY Phase 2 Trial:
Ayala presented new preliminary 6mg data from its ongoing ACCURACY Phase 2 clinical trial evaluating the safety and efficacy of AL101 monotherapy for the treatment of patients with R/M ACC harboring Notch-activating mutations. The Phase 2 ACCURACY clinical trial is an open-label, single-arm, multi-center study to assess the clinical activity of AL101 using radiographic assessments of patients with R/M ACC demonstrating disease progression within 6 months prior to dosing.

As of July 9, 2021, all 42 patients enrolled in the 6mg cohort were treated and evaluable for safety and 33 were evaluable for efficacy.

Efficacy:
All evaluable patients were assessed for efficacy for a best response by investigators using RECIST 1.1 criteria.

  • Disease control rate (DCR) (defined as partial response and stable disease) was 70% (23/33 patients).
  • Partial responses (PR) were observed in 3 patients (9%).
  • Stable disease (SD) was observed in 20 patients (61%).
  • Progressive disease (PD) was observed in 8 patients (24%).
  • Two patients were determined to be evaluable per protocol but their scans were not available for analyses.
  • Study is ongoing with several patients remaining on drug as of the cutoff date.

Safety:
AL101 6mg QW treatment in patients with R/M ACC was well tolerated with manageable side effects consistent with those observed in the 4mg QW cohort with no new adverse events (AEs) specific to the 6mg cohort.

  • Most common treatment-related (TR) AEs of any grade were diarrhea (76%), fatigue (48%), nausea (41%), hypophosphatemia (29%), vomiting (26%) and decreased appetite (26%).
  • Treatment-related diarrhea was common and occurred in 32 patients (76%) and most were grades 1 and 2. Treatment-related serious diarrhea occurred in 6 patients (14%).
  • Serious TRAEs were reported in 31% of patients with treatment-emergent AEs leading to discontinuation in 26% of patients.
  • Two patients experienced a grade 4 TRAE: one patient experienced a seizure and one patient experienced drug-induced liver injury.
  • Four treatment-emergent patient deaths occurred (10%), one of which was assessed by the investigator to be treatment related.

Ayala plans to report additional data from the ACCURACY study in 2022.

“Our new preclinical study evaluating the potential of improved efficacy of AL101 in combination with approved targeted therapies represents a promising potential approach for additive or synergistic activity of gamma secretase inhibition when combined with various mechanisms of action,” said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala. “We observed stronger tumor growth inhibition in ACC PDX models with Notch pathway genes downregulated regardless of mutational status in the combination arm of the study, as compared to AL101 monotherapy. Based on these results, we believe there is a strong rationale for a combination therapy approach to treating ACC, in addition to other cancer indications in which Notch is dysregulated. We look forward to the further development of AL101 in Notch dysregulated tumors, both as monotherapy and in combination.”

Preclinical Results of AL101 Combined with Other Drugs for Dual Targeting of Notch Dysregulated Tumors:
In this preclinical study evaluating the potential of combination therapy of AL101 in PDX models of ACC, Ayala compared the differential gene expression of ACC tumors versus normal matched tissue regardless of Notch activation status. Combination compounds were selected based on determination of the pathways that are implicated with approved oncology therapies, including inhibitors of Bcl2, HDAC, FGFR & CDK4/6. Based on a comparison of AL101 alone, each approved drug alone, and the combination of each drug with AL101, Ayala observed additive or synergistic activity of AL101 combined with agents of various mechanisms of action. AL101 in combination demonstrated significant tumor growth inhibition, including regressions, compared to each drug alone, showing significant benefit with dual targeting of Notch and other dysregulated pathways. Additionally, the study indicated that crosstalk between signaling pathways may increase the efficacy of AL101 in R/M ACC regardless of Notch mutational status. These preclinical results demonstrated a compelling rationale for potential expansion to a larger portion of ACC patients and to additional cancer indications.

About Adenoid Cystic Carcinoma (ACC)

ACC is a rare malignancy of the secretory glands including salivary glands, accounting for about 10% of all salivary gland tumors with an annual incidence of 3,400 in the U.S. There is currently no approved standard of care for patients with recurrent/metastatic ACC. Patients with locoregional disease undergo surgery and radiation therapy, with recurring disease treated by chemotherapy. ACC is an immunologically “cold” tumor that is refractory to chemotherapy, with a recurrence rate of about 60% after initial surgery. The Notch pathway has been determined to be an oncogenic driver of ACC and its dysregulation plays a key role in tumorigenesis and correlates with a distinct pattern of metastasis and a poor prognosis.

About AL101

AL101 is an investigational small molecule Gamma Secretase Inhibitor (GSI) that is designed to potently and selectively inhibit Notch 1, 2, 3 and 4, and is currently being evaluated in two Phase 2 clinical studies, ACCURACY and TENACITY, in patients with adenoid cystic carcinoma (ACC) and in patients with triple negative breast cancer (TNBC), respectively. AL101 is designed to inhibit the expression of Notch gene targets by blocking the final cleavage step by the gamma secretase required for Notch activation. Ayala obtained an exclusive, worldwide license to develop and commercialize AL101 from Bristol-Myers Squibb Company in November 2017. AL101 was granted U.S. FDA Fast Track Designation and Orphan Drug Designation for the treatment of ACC.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements relating to our development of AL101, including its treatment potential, the promise and potential impact of our preclinical or clinical trial data, and the timing of additional data from clinical trials of AL101. These forward-looking statements are based on management’s current expectations. The words “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our operations, including our preclinical studies and clinical trials, and the continuity of our business; we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our cash runway; our limited operating history and the prospects for our future viability; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in regulatory approval; our requirement to pay significant payments under product candidate licenses; the approach we are taking to discover and develop product candidates and whether it will lead to marketable products; the expense, time-consuming nature and uncertainty of clinical trials; enrollment and retention of patients; potential side effects of our product candidates; our ability to develop or to collaborate with others to develop appropriate diagnostic tests; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; risks associated with international operations; our ability to retain key personnel and to manage our growth; the potential volatility of our common stock; costs and resources of operating as a public company; unfavorable or no analyst research or reports; and securities class action litigation against us. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission (SEC) on March 24, 2021 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
Julie.seidel@sternir.com

Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com

Release – Lifeist Wellness Announces Debut of New Ticker LFST on TSX Venture Exchange

Posted on by Admin


Lifeist Wellness Announces Debut of New Ticker “LFST” on TSX Venture Exchange

 

TORONTO, Sept. 15, 2021 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. (formerly Namaste Technologies Inc.) (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) leverages advancements in science and technology to enable you to find your path to wellness, is pleased to announce that as part of its corporate name change and rebrand from “Namaste Technologies Inc.” to “Lifeist Wellness Inc.”, the Company’s common shares will continue to be publicly traded on the TSX Venture Exchange (the “TSXV”) under the new ticker symbol (“LFST”), with a new CUSIP number of 53228D106 and ISIN number of CA53228D1069. These changes are effective today at market open.

In connection with the name change, the Company also confirmed its common share purchase warrants expiring October 25, 2023 (the “2023 Warrants”), and common share purchase warrants expiring January 19, 2024 (the “2024 Warrants”), and their respective ticker symbols “LFST.WT.A” and “LFST.WT.B”, will also commence trading today on the TSXV.

The new CUSIP for the 2023 Warrants is 53228D114 and the ISIN number is CA53228D1143. The new CUSIP for the 2024 Warrants is 53228D122 and the ISIN number is CA53228D1226. No action is required by existing security holders of the Company with respect to the name change. Outstanding common shares and warrants certificates are not affected by the name change and do not need to be exchanged.

Visit the Company’s new website to learn more about Lifeist: https://lifeist.com.

About Lifeist Wellness Inc.

Lifest (previously Namaste Technologies Inc.) is at the forefront of the post-pandemic wellness revolution requiring smart solutions. Lifeist is a portfolio wellness company leveraging advancements in science and technology to enable you to find your path to wellness. Portfolio business units include: CannMart.com that provides Canadian medical customers with a diverse selection of cannabis products from a multitude of federally licensed cultivators and its U.S. customers with access to hemp-derived CBD and smoking accessories; and CannMart’s Canadian recreational cannabis distribution business facilitating recreational sales to a number of provincial government control boards. The Company is set to launch a new nutraceuticals division in Q4 2021 with disruptive products in wellness.

Information on the Company and its many products can be accessed through the links below:

Find us at:

www.lifeist.com

Cannmart.com

everyonedoesit.co.uk

For more information please contact:
Lifeist Wellness Inc.
Meni Morim, CEO
Edward Miller, VP Investor Relations
Ph: 647-362-0390
Email: ir@lifeist.com

Source: Lifeist Wellness Inc.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Source: Lifeist Wellness Inc.

Release – Esports Entertainment Group’s ggCircuit Partners with Square on Retail Integration Software

Posted on by Admin

 


Esports Entertainment Group’s ggCircuit Partners with Square on Retail Integration Software

 

Newark, New Jersey–(Newsfile Corp. – September 15, 2021) – Esports Entertainment Group, Inc. (NASDAQ: GMBL) (NASDAQ: GMBLW) (or the “Company”) and their ggCircuit business have joined forces with world-leading point of sale and payment processing provider, Square (NYSE: SQ), to create ggLeap, a premium esports center management software which will allow players to pay on screen with credit card through a QR code. ggLeap is the first esports management software to offer this feature.

“We couldn’t be more thrilled to be partnering with Square to bring this ggLeap product to launch,” said Magnus Leppäniemi, President of Esports at Esports Entertainment Group. “Players will now have the ability to purchase digital items, physical products and gaming hours directly from their computers with Apple Pay, Google Pay and more.”

ggLeap’s first version is supported in the United States, Australia, Canada, Japan, the United Kingdom and the Republic of Ireland. More locations will be announced as the Company and Square are able to integrate additional third-party payment processors.

Aside from buying PC time, users can browse through inventory items synced from the web administrator through Square. Regular inventory items and prizes will be exported and available through ggLeap and transactions completed in Square. Consumers can also use Square and their PC to buy food items while gaming.

The complete integration of ggLeap is expected to take place in September.

About Esports Entertainment Group

Esports Entertainment Group is a full stack esports and online gambling company fueled by the growth of video-gaming and the ascendance of esports with new generations. Our mission is to help connect the world at large with the future of sports entertainment in unique and enriching ways that bring fans and gamers together. Esports Entertainment Group and its affiliates are well-poised to help fans and players to stay connected and involved with their favorite esports. From traditional sports partnerships with professional NFL/NHL/NBA/FIFA teams, community-focused tournaments in a wide range of esports, and boots-on-the-ground LAN cafes, EEG has influence over the full-spectrum of esports and gaming at all levels. The Company maintains offices in New Jersey, the UK and Malta. For more information visit www.esportsentertainmentgroup.com.

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact:
U.S. Investor Relations
RedChip Companies, Inc.
Dave Gentry
407-491-4498
dave@redchip.com

Media Inquiries
brandon.apter@esportsentertainmentgroup.com

Investor Relations Inquiries
Jeff@esportsentertainmentgroup.com

Release – Indonesia Energy Discovers Oil in Its Second Back-to-Back New Well at Kruh Block

Posted on by Admin


Indonesia Energy Discovers Oil in Its Second Back-to-Back New Well at Kruh Block

 

Production from Both New Wells Expected to Commence in October  with an Expected Increase in Revenues and Production for IEC by Over 100%

JAKARTA, INDONESIA and DANVILLE, CA / ACCESSWIRE / September 15, 2021 / Indonesia Energy Corporation (NYSE American:INDO) (“IEC”), an oil and gas exploration and production company focused on Indonesia, today announced that it has discovered oil in its “Kruh 26” well after having announced in July the discovery of oil in its Kruh 25 well. These are 2 back-to-back discoveries of oil for IEC from its previously announced new drilling plans. IEC now plans to conduct stimulation work and commence production from both wells in October 2021.

It is expected that when full production from these 2 new wells is achieved (which is anticipated to occur by the end of October) that such production is expected to increase IEC’s overall daily revenues and oil production by over 100%.

IEC also announced that the Kruh 26 well took only 18 days to drill to a total depth of 3,376 feet, which is approximately half of the time that was budgeted. Both Kruh 25 and Kruh 26 were drilled under the previously announced budget of $1.5 million per well.

Additionally, approximately 111 feet of oil sands were encountered at Kruh 26 between the depths of 3,100 and 3,228 feet. This oil-bearing interval (meaning the top of the oil zone to the bottom of the oil zone) in the Kruh 26 well was thicker and therefore larger than anticipated, meaning that the total reserve potential could be larger than anticipated.

Mr. Frank Ingriselli, IEC’s President, commented “The Kruh 26 well is a significant achievement for our company, which has now completed 2 discovery wells in less that 60 days. The plan is to now stimulate and commence production next month from both wells, which is expected to double our company’s daily revenue and production. This will set us up to drill the third well for the 2021 drilling program, known as “Kruh 27″, in the fourth quarter. We look forward to continuing to deliver on our development plans and maximize returns on our investments to grow shareholder value.”

IEC also announced an update for its overall drilling program at Kruh Block. Previously, IEC announced that its three-year plan was to drill a total of 18 wells over a three-year period, with 5 of those wells drilled in 2021. IEC still plans to drill a total of 18 wells over the three-year period with 3 of those wells in 2021 and the balance of 15 more wells over the balance of the remainder of the three-year period. This slight delay was primarily caused by the permitting process in Indonesia as well as COVID-19-related delays.

Visit the IEC’s website to view a video clip of the drilling operations on the Kruh 26 well located under the Investor Media tab or visit the following link: https://www.youtube.com/watch?v=Y42NsdKXMWE

About Indonesia Energy Corporation Limited

Indonesia Energy Corporation Limited (NYSE American:INDO) is a publicly traded energy company engaged in the acquisition and development of strategic, high growth energy projects in Indonesia. IEC’s principal assets are its Kruh Block (63,000 acres) located onshore on the Island of Sumatra in Indonesia and its Citarum Block (1,000,000 acres) located onshore on the Island of Java in Indonesia. IEC is headquartered in Jakarta, Indonesia and has a representative office in Danville, California. For more information on IEC, please visit www.indo-energy.com.

Cautionary Statement Regarding Forward-Looking Statements

All statements in this press release of Indonesia Energy Corporation Limited (“IEC”) and its representatives and partners that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Acts”). In particular, when used in the preceding discussion, the words “estimates,” “believes,” “hopes,” “expects,” “intends,” “on-track”, “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Acts and are subject to the safe harbor created by the Acts. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the IEC’s control, that could cause actual results (including the results of IEC’s current and future drilling activities at Kruh Block and the impact on IEC’s results of operations as described herein) to materially and adversely differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth in the Risk Factors section of the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2020 filed on May 17, 2021 with the Securities and Exchange Commission (SEC). Copies are of such documents are available on the SEC’s website, www.sec.gov. IEC undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact:
Frank C. Ingriselli
President, Indonesia Energy Corporation Limited
Frank.Ingriselli@Indo-Energy.com

SOURCE: Indonesia Energy Corporation Limited 

Release – electroCore Announces New Patent Expanding Claims Related to Delivery of Non-Invasive Vagus Nerve Stimulation Therapy Using Mobile Devices

Posted on by Admin


electroCore Announces New Patent Expanding Claims Related to Delivery of Non-Invasive Vagus Nerve Stimulation Therapy Using Mobile Devices

 

ROCKAWAY, NJ, 
Sept. 15, 2021 (GLOBE NEWSWIRE) —  
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office has issued US Patent No. 11,097,102 to electroCore, relating to devices, systems and methods integrated with, or coupled to, smartphones that allow patients to self-treat medical conditions, such as migraine headache, by electrical non-invasive stimulation of nerves. The ‘102 patent is the 8th US patent issued to ECOR in the company’s mobile connectivity platform, with additional US and International matters pending.

electroCore is building a portfolio of Intellectual Property (IP) around smartphone-integrated and smartphone connected non-invasive therapy. This IP may provide a foundation for combining the company’s clinically proven non-invasive Vagus Nerve Stimulation (nVNS) with application-based digital health platforms that could enable health care providers to use Remote Patient Monitoring or Remote Therapeutic Monitoring reimbursement codes. That combination, in turn, may enable future business models and revenue streams for the company’s products.

“This latest patent supports our IP portfolio focused on using mobile phone systems and methods to deliver non-invasive therapy,” said JP Errico, founder, board member and investor of electroCore, and co-inventor of the new patent. “By merging smartphones and medical devices, we hope to change how external neuromodulation devices are configured to deliver therapy, creating the potential for connected devices and/or smartphones that can not only monitor biomarkers like EKGs and EEGs, but can actually deliver therapy, thereby expanding the potential reach of our platform non-invasive vagus nerve therapy to millions of patients across the globe.”

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com.

About gammaCore™
gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore (nVNS) is FDA cleared in 
the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the treatment of paroxysmal hemicrania and hemicrania continua in adults, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the 
European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

gammaCore is contraindicated for patients if they:

  • Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
  • Have a metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
  • Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

Safety and efficacy of gammaCore have not been evaluated in the following patients:

  • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  • Pediatric patients (less than 12 years)
  • Pregnant women
  • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the issuance of US and international patents providing expanded IP coverage; the possibility of future business models and revenue streams from the company’s potential combining of nVNS and smartphone or application-based technologies; the availability and impact of payer coverage, the potential of nVNS generally and gammaCore in particular and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the 
SEC available at www.sec.gov.

Investors:
Rich CockrellCG Capital
404-736-3838
ecor@cg.capital

or

Media Contact:
Jackie Dorsky
electroCore
908-313-6331
Jackie.dorsky@electrocore.com

Release – Lineage – Interim results from its ongoing 24-patient Phase 1 2a clinical study of OpRegen

Posted on by Admin


Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy

 

  • First Reported Case of Retinal Tissue Restoration Showed Zero Growth of Atrophy at 33 Months
  • Second Case of Retinal Tissue Restoration Exhibited a 10% Reduction in Atrophy Size at 8 Months
  • Third Case of Retinal Restoration is 18 Letters Above Baseline at Last Available Time Point
  • Average Difference in BCVA Between Treated and Untreated Eyes Was More Than Two ETDRS Lines (10.8 Letters Read) in Cohort 4 Patients at 9-12 Months Post-Treatment

CARLSBAD, Calif.–(BUSINESS WIRE)–Sep. 15, 2021– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported updated interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells, administered in a single surgery to the subretinal space, for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). These updated results include a minimum of 9 months of follow-up in all 12 patients treated in Cohort 4, which as a group had better baseline vision and smaller areas of GA at baseline than earlier cohorts. Overall, in the study (N=24), OpRegen has been well tolerated to date and there have been no new, unexpected ocular or systemic adverse events or serious adverse events not previously reported.

“I am particularly encouraged by the OCT findings in the second retinal restoration patient. Based on historical growth patterns, we knew this patient was a slower progressor than many other patients enrolled, and therefore less likely to benefit from treatment. Despite this, we have been able to demonstrate a reduction in the atrophic area as quickly as 2 months post-treatment and a marked slowing of disease progression,” stated Jordi Monés, M.D., Ph.D., Director of the Institut de la Màcula and 
Barcelona Macula Foundation. “Further, even in patients with an incomplete coverage of OpRegen over the primary area of atrophy, we have observed resolution of not only lesions of iRORA (incomplete retinal pigment epithelial and outer retinal atrophy), but also resolution of areas with features of cRORA, which is a state of complete loss of the RPE and outer retinal tissue. Additionally, the structural benefits may help explain the improvement in visual acuity. I eagerly look forward to new data as they are collected.”

“While competing efforts are focused on reducing the growth rate of geographic atrophy, Lineage has reported several patients whose areas of atrophy have stabilized or reduced in size. These observations, which are present across clinically-meaningful periods, indicate a reversal of the degeneration of critical retinal tissue layers which support vision, consistent with the proposed mechanism of an RPE cell transplant. Importantly, all three of the patients exhibiting restoration had confirmed historic growth rate in these areas and these data have been collected using multiple imaging modalities. The durability of the improvements to visual acuity, when coupled with the clear structural improvements we’ve seen in patients which received fuller coverage of OpRegen across their GA, strongly suggest that cell therapy may be able to achieve therapeutic benefits that are beyond the reach of targeted drugs or antibodies,” added  Brian M. Culley, Lineage CEO. “We are extremely pleased that our data is moving in a positive direction with each interim update we provide. We will continue to collect follow up data and work towards a meeting with FDA to discuss key aspects of our program. Our objective with OpRegen is to demonstrate the potential for allogeneic cell therapy to deliver the best available clinical outcomes and apply our technology to additional areas such as cancer, spinal cord injury, and other attractive opportunities.”

OpRegen Phase 1/2a Interim Clinical Results

  • Overall, 8/12 (67%) of the Cohort 4 patients’ treated eyes were at or above baseline visual acuity at their last assessment, based on per protocol scheduled visits ranging from 9 months to over 3 years post-transplant. Conversely, 9/12 (75%) of the patients’ untreated eyes were below baseline visual acuity at that assessment.
  • Improvement in best corrected visual acuity (BCVA) reached up to +24 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart for a Cohort 4 patient.
  • Comparing all treated eyes to all fellow (untreated) eyes showed an average difference of 10.8 letters read in Cohort 4 patients at their last assessment.
  • In those Cohort 4 patients with a benefit in treated as compared with fellow eye (10/12), the average difference between treated and untreated eyes was 13.6 letters read at the last assessment, which exceeded 3 years post-transplant for some patients.
  • Among the six Cohort 4 patients treated between September and 
    November 2020, three (50%) continue to exhibit marked improvements in BCVA, ranging from +5 to +18 to +24 letters read at the patient’s last scheduled assessment, which was at least 9 months post-transplant.
  • Among the other three Cohort 4 patients treated in the Fall of 2020, one patient showed a gain of +1 letter read and two patients measured -2 and -6 letters below baseline at their last assessment.
  • Across the study, in patients with previously reported structural improvements in the retina, decreases in drusen density, and a trend toward slower GA progression in treated compared to untreated eyes have continued to be present.
  • Evidence of durable engraftment of OpRegen RPE cells has extended to more than 5 years in the earliest treated patients, supporting the potential for OpRegen to be a one-time treatment.

Retinal Tissue Restoration Update

  • Three patients with evidence of retinal restoration and confirmed history of GA growth continue to demonstrate areas of retinal restoration as of their last per protocol assessments, ranging from 9 months to 33 months following treatment.
  • The first Cohort 4 patient with evidence of retinal restoration and confirmed history of GA growth, demonstrated zero growth in atrophy (GA) 33 months following treatment with OpRegen.
  • The second patient with evidence of restoration of critical retinal structures showed a 10% reduction at approximately 8 months after treatment, as assessed by square root transformation (SQRT).
    • Based on historical images of the patient’s treated eye taken ~2 years prior to treatment, the area of GA had increased from approximately 2.39 mm to approximately 2.81 mm at baseline.
    • Following OpRegen transplantation, the atrophic lesion measured approximately 2.28 mm at the patient’s month 2 per protocol assessment visit, which was smaller than the historical size of 2.39 mm from the image taken ~2 years prior to treatment.
    • Additional follow-up showed the lesion size calculated as approximately 2.53 mm at the patient’s month 8 per protocol assessment visit, which continued to be smaller than baseline.
  • The third case of restoration demonstrated clinically meaningful improvements in visual acuity, having gained +18 letters on the ETDRS chart since OpRegen transplantation, supporting the view that the changes in retinal structure observable on Optical Coherence Tomography (OCT) can result in functional benefit.

As previously described, outer retinal layer restoration was observed using clinical high-resolution OCT. To be considered as suggestive of retinal restoration, new areas of RPE monolayer with overlying ellipsoid zone, external limiting membrane, and outer nuclear layer, which were not present at the time of baseline assessment, had to be present post-treatment with OpRegen. These findings, observed in 3 Cohort 4 patients, suggest integration of the new RPE cells with functional photoreceptors in areas that previously showed no presence of these cells. These effects were most prominent in the transitional areas around the primary area of atrophy. The use of OCT allows for a more precise determination of changes in retinal thickness, organization, and overall health of the retina in areas of potential atrophy, benefits which are possible with cell transplant therapy.

The loss of RPE cells over time creates progressively larger areas of atrophy in the adult retina, leading to impaired vision or complete blindness, a condition known as atrophic AMD. Humans lack the innate ability to regenerate retinal tissue and replace lost retina cells, which led to a presumption that progression of GA may someday be slowed or halted but could not be reversed. The unique findings from the ongoing OpRegen clinical study support a different view, in which an RPE cell transplant can potentially replace or rescue retinal cells in patients who suffer from retinal lesions or degeneration. The totality of these findings supports the view that atrophic AMD is not an irreversible, degenerative condition and that some portion of diseased retinal tissue may be recoverable.

About OpRegen
OpRegen is currently being evaluated in a Phase 1/2a open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA. The study enrolled 24 patients into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with BCVA of 20/200 or worse. The fourth cohort enrolled 12 better vision patients (BCVA from 20/65 to 20/250 with smaller mean areas of GA). Cohort 4 also included patients treated with a new “thaw-and-inject” formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. The primary objective of the study is to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. OpRegen has been well tolerated to date and there have been no new, unexpected ocular or systemic adverse events or serious adverse events that have not been previously reported. OpRegen is a registered trademark of 
Cell Cure Neurosciences Ltd., a majority-owned subsidiary of 
Lineage Cell Therapeutics, Inc.

About Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is an eye disease that can blur the sharp, central vision in patients and is the leading cause of vision loss in people over the age of 60. There are two forms of AMD: dry (atrophic) AMD and wet (neovascular) AMD. Dry (atrophic) AMD is the more common of the two forms, accounting for approximately 85-90% of all cases. In atrophic AMD, parts of the macula get thinner with age and accumulations of extracellular material between Bruch’s membrane and the RPE, known as drusen, increase in number and volume, leading to a progressive loss of central vision, typically in both eyes. Global sales of the two leading wet AMD therapies were in excess of 
$10 billion in 2019. Nearly all cases of wet AMD eventually will develop the underlying atrophic AMD if the newly formed blood vessels are treated correctly. There are currently no 
U.S. Food and Drug Administration (FDA), or 
European Medicines Agency, approved treatment options available for patients with atrophic AMD.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements
Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the potential benefits of treatment with OpRegen in dry AMD patients with GA, the significance of clinical data reported to date from the ongoing Phase 1/2a study of OpRegen, including the findings of retinal tissue restoration, Lineage plans to meet with the FDA to discuss OpRegen’s clinical development, the potential utilization of OCT imaging to measure efficacy in a pivotal clinical trial of OpRegen for the treatment of dry AMD with GA, and the potential for Lineage’s investigational allogeneic cell therapies to provide safe and effective treatment for multiple, diverse serious or life threatening conditions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the 
Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the 
SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the 
SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963

Solebury Trout IR
Gitanjali Jain Ogawa
(Gogawa@soleburytrout.com)
(646) 378-2949

Russo Partners – Media Relations
Nic Johnson or  David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242

Source: 
Lineage Cell Therapeutics, Inc.

Release – CanAlaska Options Key Extension Uranium Project

Posted on by Admin


CanAlaska Options Key Extension Uranium Project

 

Vancouver, British Columbia–(Newsfile Corp. – September 15, 2021) – CanAlaska Uranium Ltd. (TSXV: CVV) (OTCQB: CVVUF) (FSE: DH7N) (“CanAlaska” or the “Company”) is pleased to announce it has entered into a Letter of Intent (“LOI”) with Durama Enterprises Limited (“Durama”), a private company, to allow CanAlaska to earn up to 100% interest in Durama’s 100%-owned 17,665 hectare Key Extension Project in the Athabasca Basin region, Saskatchewan, Canada (the “Project”) (Figure 1).



Figure 1: Key Extension Project – Project Location

The Company may earn up to a 100% interest in the Project by undertaking work and payments in a single stage over a four year period. In order to meet conditions of the four year earn-in, CanAlaska will make total cash payments of $50,000, issue 300,000 common shares in the Company subject to approval of the TSX Venture Exchange, and complete work totalling $850,000 as outlined in Table 1. In addition, a 1.5% Net Smelter Return (NSR) royalty will be granted to Durama to complete the earn-in. CanAlaska will retain the right to bring in third-party funding to complete the option requirements.

Table 1: Summary of Option Requirements

  Earned Interest (%) Cash ($) Shares (#) Work Commitment ($) Timeline (mo.)
Year 1 0 $5,000 0 0* 12
Year 2 0 $10,000 50,000 $0 12
Year 3 0 $15,000 100,000 $0 12
Year 4 100 $20,000 150,000 $850,000 12
Total 100 $50,000 300,000 $850,000 48

 

*Work must cover minimum assessment costs

The Key Extension Project lands cover the highly prospective Wollaston-Mudjatik transition zone (WMTZ) in the Southeastern Athabasca Basin (Figure 2). The Project lands have been explored with historical regional and project scale ground and airborne geophysical surveys, with additional focused prospecting programs targeting lake sediment and boulder anomalies. The regional geophysical surveys map linear magnetic low features with corresponding electromagnetic (EM) conductors on the eastern-most claim of the Project, typical of the Lower Wollaston Domain. On the Western claims, the conductors are generally shorter strike length discontinuous features, typical of the Mudjatik Domain. Focused airborne magnetics and VTEM (Versatile Time Domain Electromagnetic) surveys were completed by past operators of the Project in the early 2000’s, outlining a prominent 10 kilometre long northeast-trending conductor corridor that is coincident with a magnetic lineament that trends toward the historically producing Key Lake uranium deposits, Deilmann and Gaertner (Figure 2), and swings to the south along the Wollaston-Mudjatik boundary.



Figure 2: Key Extension Project – Target Areas

Despite the prolonged regional exploration and Key Lake deposit discoveries in the area, the Project lands have only undergone minimal drill testing in the late 1970’s consisting of shallow regional tests of conductors. Extensive drilling has been completed in and around the Key Lake deposits and associated showings, located approximately 10 km from the northeastern project boundary. The Key Lake deposits consist of a series of east-northeast striking pods of unconformity associated uranium mineralization, which have historically produced over 150 million lbs U3O8 from the Gaertner and Deilmann open pits. The deposit-controlling Key Lake structure and stratigraphy are interpreted to trend onto the Project lands based on the magnetic lineaments and conductor patterns in the geophysical data.

CanAlaska CEO, Cory Belyk, comments, “CanAlaska is very pleased to acquire this option on the Key Extension Project. An opportunity to acquire a vastly under-explored 10 km section of the Key Lake structure and stratigraphy ahead of a sustained uranium market up-turn which we believe is coming is a significant achievement for our shareholders. Newly-defined exploration criteria and methods for discovery of basement-hosted Athabasca Basin uranium deposits has yet to be applied on this project. The CanAlaska team is looking forward to the next phase of exploration on Key Extension.”

About CanAlaska Uranium

CanAlaska Uranium Ltd. (TSXV: CVV) (OTCQB: CVVUF) (FSE: DH7N) holds interests in approximately 214,000 hectares (530,000 acres), in Canada’s Athabasca Basin – the “Saudi Arabia of Uranium.” CanAlaska’s strategic holdings have attracted major international mining companies. CanAlaska is currently working with Cameco and Denison at two of the Company’s properties in the Eastern Athabasca Basin. CanAlaska is a project generator positioned for discovery success in the world’s richest uranium district. The Company also holds properties prospective for nickel, copper, gold and diamonds. For further information visit www.canalaska.com.

The qualified technical person for this news release is Nathan Bridge, MSc., P.Geo., CanAlaska’s Vice President, Exploration.

On behalf of the Board of Directors
“Peter Dasler”
Peter Dasler, M.Sc., P.Geo.
President
CanAlaska Uranium Ltd.

Contacts:

Cory Belyk, Executive VP and CEO
Tel: +1.604.688.3211 x 306
Email: cbelyk@canalaska.com

Peter Dasler, President
Tel: +1.604.688.3211 x 138
Email: info@canalaska.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information

All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.